Home›Psychiatry› Psilocybin shows more robust evidence for sustained effects in treatment-resistant depression than ayahuasca
Psilocybin shows more robust evidence for sustained effects in treatment-resistant depression than ayahuascaPsilocybin and Ayahuasca Show Potential for Treatment-Resistant Depression
Frontiers in MedicinePublished September 16, 2026DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that psilocybin shows more robust evidence for sustained effects in treatment-resistant depression than ayahuasca.
This narrative review synthesizes current evidence regarding the use of psilocybin and ayahuasca for the treatment of treatment-resistant depression. The review focuses on the efficacy of these substances in reducing depressive symptoms and the durability of those effects over time.
The authors conclude that both psilocybin and ayahuasca are associated with rapid reductions in depressive symptoms. Specifically, psilocybin is noted to have more robust evidence for sustained effects compared to ayahuasca.
Several limitations are noted, including the use of highly controlled environments, stringent inclusion and exclusion criteria, and the exclusion of patients with comorbidities, high suicide risk, or polypharmacy. Other noted limitations include challenges in maintaining blinding, high participant expectations, small sample sizes, and under-addressed ethical considerations regarding informed consent and potential for enduring personality or cognitive changes.
Clinical application is currently limited because the evidence primarily reflects outcomes in clinically stable and selected subpopulations rather than real-world patients with treatment-resistant depression. The reliance on adjunct psychotherapy and the lack of diverse patient profiles in trials may limit the generalizability of these findings to broader clinical practice.
How this fits prior evidence
This narrative review extends prior coverage of psilocybin. While previous reports noted that microdosing psilocybin is associated with reported well-being and mental health benefits, this review specifically addresses treatment-resistant depression. It also builds upon evidence of dose-dependent functional connectivity changes in healthy volunteers by focusing on clinical outcomes in patients with depressive symptoms.
This review looked at how psilocybin and ayahuasca affect people with treatment-resistant depression. The review found that both substances were linked to rapid reductions in depressive symptoms. However, the evidence for psilocybin was noted as more robust when it came to maintaining these effects over time.
It is important to note that these findings come from studies with very specific limitations. Many of the participants were in highly controlled settings and did not have other health problems. Because the studies used small groups and strict rules for who could join, the results might not apply to everyone with depression in the real world.
Because of these factors, the results are not yet enough to change standard medical practice. The research is still early and focuses on a specific group of patients. You should talk to your doctor to understand how these findings might relate to your specific health needs.
What this means for you:
Psilocybin and ayahuasca show promise for depression, but current evidence is limited by small, controlled studies.
Common questions
What did the study find about psilocybin and depression?
The review found that psilocybin was linked to rapid reductions in depressive symptoms. The evidence also suggested that psilocybin showed more robust results for sustained effects compared to other findings. However, these results were observed in a very specific, controlled group of patients.
Is this treatment available for everyone with depression?
The current evidence is not yet enough to change standard medical practice. The studies included only stable patients in controlled settings and excluded people with other health issues. Because of these limitations, the results may not apply to all patients in real-world settings.
What are the limitations of this research?
The research faced several challenges, including small sample sizes and the use of highly controlled environments. There were also concerns regarding the difficulty of keeping studies blinded and the ethical considerations of how these substances might affect personality or cognition over time.
BackgroundTreatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for understanding their clinical utility.MethodsWe conducted a narrative review of literature on psilocybin and ayahuasca in adult patients with TRD, focusing on safety, efficacy, and study design characteristics. PubMed and PsycINFO databases were searched from inception to August 2025. Studies were assessed for clinical outcomes, side effect profiles, and methodological and ethical limitations, including participant selection, blinding, and informed consent procedures.ResultsBoth psilocybin and ayahuasca demonstrate rapid reductions in depressive symptoms, with psilocybin showing more robust evidence for sustained effects. However, clinical trials are predominantly conducted in highly controlled environments with stringent inclusion and exclusion criteria, systematically excluding patients with comorbidities, high suicide risk, or polypharmacy. Challenges in maintaining blinding, high participant expectations, small sample sizes, and reliance on adjunct psychotherapy further limit the interpretation and generalizability of findings. Ethical considerations, including informed consent for intense psychedelic experiences and the potential for enduring personality or cognitive changes, remain under-addressed. Consequently, current evidence primarily reflects outcomes in clinically stable and selected subpopulations, rather than real-world TRD patients.ConclusionPsychedelic-assisted therapies hold significant potential for TRD, but their current evidence base is constrained by methodological and ethical limitations. Future research should prioritize large, representative trials, standardized protocols, and robust safeguards to ensure both scientific validity and patient safety. Unlike previous reviews that primarily synthesized efficacy outcomes across different psychedelic compounds, the present narrative review specifically compares psilocybin and ayahuasca within the framework of treatment-resistant depression while integrating methodological, ethical and real-world implementation issues. This perspective aims at complementing the existing evidence by highlighting factors that may influence future clinical translation.
